Skip to content

A Registry Based Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With Spinal Muscular Atrophy

A Registry-Based Parallel Group Randomized-Controlled Trial of an Upper Limb Exergaming Intervention for Children and Adolescents With Spinal Muscular Atrophy, With an Optional Open-Label Extension

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06396325
Acronym
INFORM SMA
Enrollment
22
Registered
2024-05-02
Start date
2024-11-01
Completion date
2027-12-31
Last updated
2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Muscular Atrophy

Keywords

spinal muscular atrophy, rehabilitation, Exergaming, Pediatrics, Randomized-controlled trial

Brief summary

This is a multisite randomized controlled registry-based trial to evaluate the efficacy of an 8-week home-based exergaming intervention as compared to usual care on occupational satisfaction of children and youth (8-18 years old age) with spinal muscular atrophy (SMA).

Detailed description

This multisite randomized controlled registry-based trial will evaluate the efficacy of a home-based exergaming intervention, as compared to usual care, on occupational satisfaction of children and youth (aged 8-18 years old) with SMA. Participants in the intervention arm will play the exergame, Tales from the Magic Keep™ on the Azure Kinect platform, 3 times per week, for at least 20 minutes, over 8 weeks (total 8 hours), and continue to access their regular physical activities and rehabilitation services. Those in the usual care arm will continue to access their regular physical activities and rehabilitation services. Occupational satisfaction will be assessed using the Canadian Occupational Performance Measure (COPM) at 8 weeks.

Interventions

OTHERTales from the Magic Keep™

Exergame targeting upper limb and trunk movement designed for use on the Microsoft Azure Kinect Dose: At least 3 times a week for 20 minutes over 8 weeks (8 hours total) Continue with regularly accessed physical activities and rehabilitation services

OTHERUsual Care

Continue with regularly accessed physical activities and rehabilitation services

Sponsors

Maryam Oskoui, MD, MSc, FRCPC, FAAN
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
8 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Confirmed genetic diagnosis of 5q SMA * Age at screening: Aged 8-18 years old * Participant is able to stay seated independently without support for at least 10 seconds * Participants has a score of at least 2 points in entry item A of the RULM (i.e., Can raise 1 or 2 hands to the mouth but cannot raise a 200 g weight in it to the mouth) * Treated with disease-modifying therapy * Signed ICF

Exclusion criteria

* Inability to comply with study procedures according to the site investigator, prior to randomization * Severe scoliosis or contractures that would interfere with gameplay or with successful completion of functional assessments, as confirmed by the clinical evaluator * Planned orthopedic surgery 6 months prior to or throughout intervention and follow-up period (16 weeks post randomization) * Inability to read in English or French

Design outcomes

Primary

MeasureTime frameDescription
Satisfaction with occupational performanceBaseline to 16 weeksCanadian Occupational Performance Measure (COPM) Satisfaction

Secondary

MeasureTime frameDescription
Self-reported fatigueBaseline to 16 weeksPatient-Reported Outcomes Measurement Information System (PROMIS-SF)
Independence performing activities of daily livingBaseline to 16 weeksSMA Independence Scale (SMAIS)
Upper limb motor activityBaseline to 16 weeksMedian and 99th percentile of upper limb rotational effort and vertical wrist acceleration derived from data captured by the Syde wearable device

Countries

Canada

Contacts

Primary ContactMbaye Ndiaye
mbaye.ndiaye@muhc.mcgill.ca5149341934

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026